News
Medical technology company Masimo has been facing off with Apple in court since 2020, and while Masimo has scored some wins, ...
7h
Zacks Investment Research on MSN3 Reasons Why Growth Investors Shouldn't Overlook Masimo (MASI)Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find ...
StockStory.org on MSN2d
Masimo’s (NASDAQ:MASI) Q2: Beats On Revenue But Stock DropsMedical tech company Masimo (NASDAQ:MASI) reported Q2 CY2025 results , with sales up 7.9% year on year to $370.9 million. The ...
Masimo Corp (MASI) reports robust earnings growth and outlines strategic advancements in healthcare technology amidst tariff ...
Second Quarter 2025 Results Key Financial Results Revenue: US$370.9m (down 25% from 2Q ...
Masimo (Nasdaq: MASI) shares dipped after hours today on second-quarter results that came in ahead of the consensus forecast.
IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Masimo Corp. (MASI) on Tuesday reported second-quarter profit of $51.3 million. On a per-share basis, the Irvine, California-based company said it had ...
Apple removed blood oxygen monitoring from the Apple Watch in early 2024. Somebody has to blink for it to return, and it ...
Apple asked a U.S. appeals court on Monday to overturn a trade tribunal's decision which forced it to remove blood-oxygen ...
For over three years now, Apple has been entrenched in a messy legal battle over a single feature on the Apple Watch — and Apple’s opponent, medical device maker Masimo, seems confident it can ...
The I.T.C. case is only one front in the battle between Masimo and Apple. In 2020, Masimo sued Apple in Federal District Court in California, alleging theft of trade secrets.
The stock price of Masimo Corporation, a medical devices company best known for its remote patient monitoring systems, reached its all-time high of $287 just last week before a recent decline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results